Who owns UroGen Pharma Ltd.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of URGN from SEC Form 13F filings across 220 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 220 institutions disclosed 40.6M shares of UroGen Pharma Ltd. worth $1.73B — about 80.2% of shares outstanding; the largest disclosed holder is RTW INVESTMENTS, LP. Source: SEC Form 13F filings, parsed by EvidInvest.
220
13F holders
$1.73B
value, 2026 filers
80.2%
of shares outstanding (40.6M sh)
52
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of URGN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 4.5M | $184.6M | 1.9% | 9% | 0.0% |
| 2 | BlackRock, Inc. | 3.1M | $126.3M | 0.0% | 6.1% | -2.9% |
| 3 | Kynam Capital Management, LP | 2.4M | $98.9M | 5.5% | 4.8% | 0.0% |
| 4 | Jefferies Financial Group Inc. | 2.2M | $89.4M | 0.7% | 4.4% | 0.0% |
| 5 | MORGAN STANLEY | 2.2M | $88.4M | 0.0% | 4.3% | -15.6% |
| 6 | ACORN CAPITAL ADVISORS, LLC | 1.6M | $67.0M | 18.4% | 3.3% | -1.5% |
| 7 | Opaleye Management Inc. | 1.4M | $58.5M | 6.6% | 2.8% | 0.0% |
| 8 | AMERICAN CENTURY COMPANIES INC | 1.4M | $55.9M | 0.0% | 2.7% | -18.4% |
| 9 | D. E. Shaw & Co., Inc. | 1.3M | $52.2M | 0.0% | 2.5% | +12.0% |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.1M | $46.7M | 5.5% | 2.3% | -11.8% |
| 11 | ORBIMED ADVISORS LLC | 988,487 | $40.2M | 0.7% | 2% | +46.2% |
| 12 | STATE STREET CORP | 975,787 | $39.6M | 0.0% | 1.9% | -2.7% |
| 13 | FRONTIER CAPITAL MANAGEMENT CO LLC | 936,144 | $38.0M | 0.4% | 1.9% | -37.9% |
| 14 | MPM BIOIMPACT LLC | 909,691 | $37.0M | 2.7% | 1.8% | -2.5% |
| 15 | GOLDMAN SACHS GROUP INC | 848,342 | $34.5M | 0.0% | 1.7% | +3.5% |
| 16 | Migdal Insurance & Financial Holdings Ltd. | 770,909 | $31.3M | 0.2% | 1.5% | 0.0% |
| 17 | Parkman Healthcare Partners LLC | 750,202 | $30.5M | 2.7% | 1.5% | +331.0% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 617,513 | $25.1M | 0.0% | 1.2% | +1.2% |
| 19 | Woodline Partners LP | 500,726 | $20.3M | 0.1% | 1% | 0.0% |
| 20 | Boxer Capital Management, LLC | 500,000 | $20.3M | 1.8% | 1% | 0.0% |
| 21 | Elmind Capital, LP | 491,100 | $20.0M | 4.9% | 1% | +309.3% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 462,075 | $18.8M | 0.0% | 0.9% | +1.2% |
| 23 | TWO SIGMA INVESTMENTS, LP | 406,299 | $16.5M | 0.0% | 0.8% | +172.8% |
| 24 | ADAR1 Capital Management, LLC | 369,785 | $15.0M | 0.7% | 0.7% | +46.5% |
| 25 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC.NEW | 366,973 | $14.9M | 0.0% | 0.7% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.